A Phase 2 Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection (LIMT)

Trial Profile

A Phase 2 Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection (LIMT)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 11 May 2018

At a glance

  • Drugs Peginterferon lambda-1a (Primary)
  • Indications Hepatitis D
  • Focus Therapeutic Use
  • Acronyms LIMT; LIMT HDV
  • Sponsors Eiger BioPharmaceuticals
  • Most Recent Events

    • 11 May 2018 According to an Eiger BioPharmaceuticals, Inc. media release, the company aims to complete dosing in this trial in 2018.
    • 24 Oct 2017 Interim results (n=20) presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases
    • 23 Oct 2017 Interim results (24 weeks) presented at the American Association for the Study of Liver Diseases (AASLD) 2017 meeting, according to an Eiger BioPharmaceuticals Inc. media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top